When: Q3 2026 earnings mid-October

Then: Full reassessment regardless of intervening signals

HOLD with stop at $384, no new adds, position sizing review, protective puts at $380 strike for 60 days, and pre-defined automatic trimming rules if Q3 earnings disappoint

• Tepper's full position liquidation in one quarter is a sentiment signal, not noise — remaining overhang could re-price on any negative catalyst
• MACD histogram at 0.18 is not a reversal: MACD line still negative at -5.23, signal line at -5.41, 50 SMA declining — medium-term downtrend intact
• Bear case downside to $347 (9.5%) is not the floor — UNH traded as low as $256 (35% drawdown from current levels) in past 52 weeks
• Q1 cost-of-revenue improvement ($94.7B to $86.3B) reflects seasonal low utilization; Q2/Q3 are peak utilization quarters that will test structural claims
• Forward EPS of $22.44 implies 44% jump from $15.58 TTM on single quarter data with seasonal tailwind — thin evidence for large move
• October 1 prior-auth removal covering 30% of services is double-edged: could spike utilization and blow out MLR in Q3 earnings
• Goodwill of $110.5B (35% of total assets) tied to Optum/Change Healthcare acquisitions is vulnerable to impairment on utilization deterioration
• Sector multiples down 25% over two years per Trefis — not a floor but a trajectory
• Forward PE of 17.7x based on consensus estimates from same Q1 print; one soft quarter could push PE to 22-23x
• Polymarket pricing 89% probability of zero rate cuts in 2026 creates hawkish macro headwind for managed-care sector
• Supports Neutral Analyst's $413 reclaim/$384 break approach as paying 4.3% insurance premium against asymmetric downside
• Recommends reviewing position sizing for current volatility regime and considering protective puts at $380 strike for 60 days

→ vs aggressive: MACD histogram of 0.18 is noise, not reversal — MACD line still negative at -5.23, signal line at -5.41, 50 SMA declining; real bullish confirmation requires MACD line to cross above signal line, which hasn't happened

→ vs aggressive: $347 bear case target at 14x forward multiple is not a valuation floor — $256 low (35% drawdown) is in recent memory; 200 SMA catches tests until it doesn't

→ vs aggressive: Q1 data ($94.7B to $86.3B cost of revenue) had seasonal tailwind from deductible reset; forward EPS of $22.44 (44% jump from $15.58 TTM) is thin evidence for large implied move

→ vs aggressive: October 1 catalyst is double-edged sword — prior-auth removal could spike utilization and blow out MLR in Q3 earnings, which come out mid-October

→ vs aggressive: Goodwill impairments are technically non-cash but signal acquired business underperformance and force multiple re-rating; $110.5B goodwill at risk from Optum/Change issues

→ vs aggressive: 6.8% FCF yield and 17.7x forward PE are not static — FCF yield moves against us on cash flow disappointment; forward PE expands to 22-23x on revised-down estimates

→ vs aggressive: Buying 4-6 weeks ahead of catalyst is not 'aggressive capital preservation' — it's paying 4.3% for confirmation when 4.3% is actually insurance against breaking $384

→ vs neutral: Waiting for $413 reclaim or $384 break is defensible risk management, not leaving money on the table — it's paying a small insurance premium against asymmetric downside

HOLD with refined framework including $413 entry confirmation, $384 hard stop, $390 soft warning level, and staged catalyst rules

• Both aggressive and conservative analysts agree on HOLD action despite framing differences
• The stock is in a no-man's-land between $384 and $413 with medium-term bearish but long-term intact trends
• HOLD is the correct call - neither buy nor sell at $396
• Buying confirmation at $413 provides information value versus paying 4.3 percent premium without it
• 200 SMA at $384 is the appropriate hard stop level
• $390 soft warning level triggers discretionary review for two consecutive closes below on rising volume
• Position sizing review depends on original rationale - reduce 20 to 30 percent only if sized for stable uptrend
• October 1 prior-auth removal catalyst is double-edged with Q3 utilization as the real test
• 6.8 percent FCF yield, 2.38 percent dividend, and 0.63 beta support defensive thesis
• Clear rules for $413, $384, $390, and Q3 earnings needed to avoid debate on each $2 move

→ vs aggressive: Dismissive framing of confirmation as 'paying retail' ignores that $413 reclaim with rising volume and MACD crossover is information, not just cost

→ vs aggressive: Multiple expansion scenario to 22-25x assumes benign macro, but 89 percent probability of zero rate cuts in 2026 means higher-for-longer pressures discount rates applied to multi-year earnings streams

→ vs aggressive: Treating Tepper exit as 'fully absorbed' is overconfident - the overhang reactivates on any soft print, regulatory headline, or peer warning

→ vs conservative: Comparing $256 low to $347 setup is misleading - $256 was different regime with MLR spike, cyberattack aftermath, and worse macro backdrop; operational progress at $347 is structurally different

→ vs conservative: Framing Q1 as 'seasonally low utilization' dismisses real structural improvements: 640 basis points gross margin recovery and $8.4 billion cost of revenue drop are repricing, network tightening, and benefit design changes, not seasonal artifacts

→ vs conservative: Protective puts suggestion contradicts the hard stop logic - if $384 stop works, adding $380 puts is duplicate insurance; pick one discipline and stick with it